Advances in multiple sclerosis research cited

New advances are helping patients suffering from multiple sclerosis. In Advancing on MS: New drugs and hopes for a vaccine, the Philadelphia Inquirer reports on promising research:
Barely 15 years ago, doctors could do nothing to change the course of multiple sclerosis, the disabling neurological disease that strikes in the prime of adulthood.

Today, six drugs are approved to decrease the periodic immune attacks that underlie MS, another six are in final human testing, and dozens more are in development. Researchers have zeroed in on genetic and environmental risk factors; a common virus may play a role in activating the disease. And the ultimate goal - regrowing damaged nerves - is no longer a pipe dream....Circumstantial evidence has long supported the idea that MS is triggered by an infectious agent, perhaps a virus or bacteria, in people with genetic susceptibility.

Now, research is bolstering suspicion that Epstein-Barr virus is the culprit.

Epstein-Barr is a ubiquitious microbe that infects about 95 percent of American adults. Often there are no symptoms, but more than a third of infected adolescents and young adults develop the fever, sore throat and fatigue of infectious mononucleosis.

A history of mono increases the small risk of MS as much as threefold. Studies suggest Epstein-Barr also plays a role in lupus, another autoimmune disease.
Interestingly, some "natural" substances are found to be helpful in combination with pharmaceutical approaches: "At Jefferson, both glucosamine, the dietary supplement for joints, and a compound derived from ordinary soy have been shown to partly restore walking ability in mice with an MS-like disease."
The Law Offices of Michael H. Cohen offers corporate legal services, litigation consultation, and expertise in health law with a unique focus on holistic, alternative, complementary, and integrative medical therapies. The law firm represents medical doctors, allied health professionals (from psychologists to nurses and dentists) and other clinicians (from chiropractors to naturopathic physicians, massage therapists, and acupuncturists), entrepreneurs, hospitals, and educational organizations, health care institutions, and individuals and corporations.

Michael H. Cohen is Principal in Law Offices of Michael H. Cohen and also President of a nonprofit organization exploring legal, regulatory, ethical, and health policy issues in the judicious integration of complementary and alternative medical therapies (such as acupuncture and traditional oriental medicine, chiropractic, naturopathic medicine, homeopathy, massage therapy, energy healing, and herbal medicine) and conventional clinical care. Michael H. Cohen is author of books on health care law, regulation, ethics and policy dealing with complementary, alternative and integrative medicine, including Healing at the Borderland of Medicine and Religion, Complementary and Alternative Medicine: Legal Boundaries and Regulatory Perspectives (1998), Beyond Complementary Medicine: Legal and Ethical Perspectives on Health Care and Human Evolution (2000), and Future Medicine: Ethical Dilemmas, Regulatory Challenges, and Therapeutic Pathways to Health Care and Healing in Human Transformation (2003).
Sponsorship Sponsorship
Health care and corporate lawyer Michael H. Cohen has been admitted to the Bar of California, Massachusetts, New York, and Washington D.C. In addition to qualifying as a U.S. attorney, he has been admitted and to the Bar of England and Wales as a Solicitor (non-practicing). For more information regarding the law practice of attorney Michael H. Cohen, see the FAQs for the Law Offices of Michael H. Cohen. Thank you for visiting the Complementary and Alternative Medicine Law Blog.